Scott Nelson Live

Scott Nelson Live

By Scott NelsonBusinessEntrepreneurship
Download on the App Store

All Scott Nelson Live episodes

  • Translating Academic IP into a Medtech Startup: Interview with Echopoint Medical CEO Antony Odell

    In this episode, we sat down with Antony Odell, co-founder and CEO of Echopoint Medical.

    Echopoint is a London-based UCL spinout developing iKOr, an optical microcatheter for coronary diagnostics.

    Antony brings over 30 years of medtech experience across Johnson & Johnson, Fresenius, and Stryker, before transitioning into startups as CEO of Tayside Flow Technologies and Tissue Regenix. He holds a BSc in Physiology and Biochemistry.

    In this interview, Antony discusses translating academic IP into a commercial device, choosing early clinical sites to balance speed and learning, managing non-dilutive funding as a long-term discipline, and outlines the most important responsibilities of an early-stage medtech CEO.

    KEY MOMENTS FROM THE INTERVIEW

    • (03:06) - How Antony’s career centered on translating clinical insights into commercial reality

    • (05:54) - What Echopoint's iKOr does, and why 40% of cath lab patients leave without a diagnosis

    • (12:13) - How Echopoint landed its first U.S. clinical site, and what that means for the company

    • (13:48) - What to assess before spinning out an academic idea, and why clinician input is the first real test

    • (20:14) - Why Echopoint chose Barts over typical sites for its first-in-human study

    • (22:58) - How getting too close to one clinical site can lead to dangerous groupthink

    • (30:54) - Why non-dilutive funding belongs on the board agenda permanently

    • (39:54) - How CEOs should manage boards, control information flow, and avoid becoming a “glorified note-taker”

    • 53 min
    • Why Early Revenue is the Most Credible Proof in Medtech: Interview with restor3d CEO Kurt Jacobus

      In this episode, we sat down with Kurt Jacobus, co-founder and CEO of restor3d.

      restor3d provides patient-specific orthopedic implants using 3D printing and advanced software.

      Kurt has over two decades of experience in medtech entrepreneurship, including successful exits to Enovis and NuVasive. Prior to his career in medical devices, Kurt was a consultant at McKinsey & Company. He holds a PhD in Mechanical Engineering and is an Adjunct Professor at Georgia Tech. 

      In this interview, Kurt discusses how restor3d used the FDA's 520(b) pathway to generate revenue and regulatory proof simultaneously, why self-regulating beyond FDA requirements makes submissions a competitive barrier, and how to approach investor relationships and board construction with long-term thinking.

      KEY MOMENTS FROM THE INTERVIEW

      • (03:21) - How Kurt went from wanting to build race cars to 20 years of orthopedic entrepreneurship

      • (06:03) - How restor3d’s patient-specific implants challenge the “8 sizes fit 8 billion people” model

      • (15:36) - Why early-stage companies should “ring the cash register” as soon as possible

      • (17:16) - How a 520(b) pathway helped restor3d generate revenue before full FDA clearance

      • (31:48) - How restor3d treats every FDA submission like a PhD thesis and holds itself to standards beyond what regulators ask for

      • (35:24) - What Kurt learned from restor3d’s limited market release

      • (40:03) - How Kurt raised is last$100M+ round, and why fundraising is really a networking game

      • (45:13) - What makes a great board, and how the wrong one can quietly derail a company

      • 56 min
      • Finding the Clinical Need Hiding in Plain Sight: Interview with LightForce CEO Alfred Griffin

        In this episode, we sat down with Alfred Griffin, co-founder and CEO of LightForce.

        LightForce is the developer of the world's first fully customized 3D-printed bracket system directly personalized for each patient's digital treatment plan.

        Alfred holds a DMD and PhD in Craniofacial Biology from the Medical University of South Carolina and completed his orthodontic residency at Harvard School of Dental Medicine, where he currently serves as faculty and the Board of Fellows. An ABO-certified practicing orthodontist, he continues to see patients every month while running the company.

        In this interview, Alfred shares how applying existing technology to an overlooked market can unlock a larger opportunity, how adoption friction is a design problem, and why scaling a new category requires treating operations as a core product investment.

        KEY MOMENTS FROM THE INTERVIEW

        • (02:43) - How growing up in a family of dentists shaped Alfred’s path into orthodontics

        • (07:41) - How LightForce uses digital planning and 3D printing to create fully customized braces

        • (08:48) - Why LightForce isn’t a brilliant idea, but an obvious fix for the teen braces market that aligners missed

        • (12:19) - How LightForce is like Google Maps for teeth, eliminating detours and removing inefficiencies

        • (17:30) - How Alfred built LightForce around his clinical strengths and hired for experience to round out the gaps

        • (30:56) - The 3-part secret to LightForce adoption by physicians

        • (36:42) - How Alfred approaches fundraising, matching investors to the company’s stage and needs

        • (41:51) - About LightForce’s digital factories and why they’re the company’s core moat

        • 51 min
        • Regulatory Rigor as a Competitive Moat: Interview with Osteoboost CEO Laura Yecies

          In this episode, we sat down with Laura Yecies, CEO of Osteoboost.

          Osteoboost is the first FDA-cleared drug-free prescription treatment for osteopenia in postmenopausal women.

          Laura brings over 30 years of experience across technology, digital health, and medical innovation, with a focus on overlooked gaps in women's health. She previously served as CEO of SugarSync (acquired by J2 Global), Catchsold (sold to Apple), and Neurosync, a neurotechnology company. 

          In this interview, Laura discusses why choosing a Class II prescription path creates a regulatory moat, how designing for daily comfort and a frictionless experience drives commercialization, and how channeling early patient demand turned a waitlist into a launch strategy.

          KEY MOMENTS FROM THE INTERVIEW

          • (02:49) - An overview of Laura’s background and her transition from consumer tech to medtech

          • (04:53) - The problem Osteoboost is solving — and why bone health remains a massive unmet need

          • (08:31) - How Osteoboost designed its device with the consumer experience in mind

          • (15:44) - Why Osteoboost chose a Class II regulatory pathway over an easier path

          • (19:50) - How to design clinical trials that reflect real-world use and drive patient compliance

          • (25:01) - How early demand and a waitlist validated strong consumer pull before full commercialization

          • (28:48) - Why Laura believed the problem wasn’t demand — it was lack of options

          • (33:57) - How patients can become a powerful “sales force” in healthcare

          • (38:20) - Why shifting consumer behavior is making self-pay more viable — with reimbursement coming later

          • 55 min
          • What It Takes to Win Physician Confidence: Interview with Secure Closure CEO Stephen Belcher

            In this episode, we sat down with Stephen Belcher, co-founder and CEO of Secure Closure.

            Secure Closure is developing Quattro-Close, a device designed for large-bore femoral access sites.

            Trained as a veterinarian, Stephen has spent more than 25 years in the medical device industry, with deep experience in vascular access and closure technologies. He previously held commercial and marketing roles at Abbott Vascular, Edwards Lifesciences, and Teleflex, where he was involved in launching key closure devices, including ProGlide, StarClose, SAPIEN 3, and MANTA.

            In this interview, Stephen discusses what actually drives physician adoption in high-stakes procedural fields, how real-world clinical and patient challenges should shape device design decisions, and what early-stage fundraising looks like when traditional medtech VCs are increasingly committing capital at later stages.

            KEY MOMENTS FROM THE INTERVIEW

            • (02:52) - An overview of Stephen Belcher’s background and the journey that led him to founding Secure Closure

            • (08:04) - How Quattro-Close works, using a purse-string suture and extravascular clip for reliable closure and artery preservation

            • (13:53) - Stephen's lessons learned from large strategics and how he simplifies them for a startup

            • (19:22) - How Stephen spent nearly a decade iterating on the device through failures, funding gaps, and small incremental progress

            • (23:36) - Why physician adoption depends on consistent outcomes, not early excitement or new features

            • (28:10) - How Quattro-Close is designed around the real unmet need, reducing complications while preserving the artery for future procedures

            • (34:14) - His approach to first-in-human, site selection, and generating data that can stand up to FDA scrutiny

            • (40:31) - How Stephen navigates early fundraising

            • 51 min
            • The Four-Risk Framework for Evaluating Medtech Opportunities: Interview with SonoVascular CEO Daniel Estay

              In this episode, we sat down with Daniel Estay, founder and CEO of SonoVascular.

              SonoVascular has developed a novel mechanical-pharmaco ultrasound facilitated thrombectomy system, SonoThrombectomy, that utilizes microbubble-mediated cavitation as a core enabling mechanism to remove blood clots more effectively.

              Dan has over 35 years of global medtech experience, including business development roles at Johnson & Johnson, where he worked on deals that helped create the world's first drug-eluting stent, and six years leading Abbott's cardiovascular device business across Asia-Pacific and Japan. He also serves as a Mentor-in-Residence at Duke University's New Ventures group.

              In this interview, Dan discusses how to evaluate whether a medtech opportunity is commercially viable beyond technical feasibility, how trust and long-standing relationships matter more than geography when selecting first-in-human sites, and why cap table strategy requires deliberate thinking from the earliest stages — including when to transition from convertible notes to priced rounds.

              KEY MOMENTS FROM THE INTERVIEW

              • (02:52) - An overview of Dan Estay’s background and the journey that led him to SonoVascular

              • (08:04) - The core idea behind SonoVascular — combining mechanical and pharmacological therapy to treat thrombosis

              • (13:33) - Why differentiation alone isn’t enough, and how Dan evaluates market size and viability before building

              • (18:38) - The four risks every medtech founder should assess: technical, clinical, regulatory, and market

              • (21:55) - Why Dan chose Chile for SonoVascular's FIH study and what he looks for in a clinical trial site

              • (29:05) - Why Dan would rethink his use of convertible notes and approach the cap table more strategically

              • (38:28) - Why grants should supplement your funding strategy, not lead it

              • (42:46) - What Dan looks for when hiring for startups

              • 52 min
              • Testing Demand Before Perfecting Technology: Interview with Eyebot CEO Matthias Hofmann

                In this episode, we sat down with Matthias Hofmann, CEO of Eyebot.

                Eyebot is commercializing retail kiosks that deliver quick, efficient vision testing.

                Before Eyebot, Matthias led product development at Formlabs and served as an R&D lead at EyeNetra, where he helped bring the first smartphone-based vision test to market. He holds a Ph.D. in Electrical Engineering with graduate work in vision science and optics. 

                In this interview, Matthias discusses how early missteps informed Eyebot's strategy, how he proved demand before raising capital, and how iterative clinical studies established commercial credibility — along with his unconventional advice on fundraising.

                KEY MOMENTS FROM THE INTERVIEW

                • (02:53) - Overview of Matthias’s background and the journey that led him into vision care startups

                • (05:58) - Lessons from solving the right problem the wrong way at EyeNetra

                • (08:44) - Why Eyebot chose a kiosk interface instead of smartphone vision testing

                • (11:08) - How Eyebot designed its system to deliver accurate prescriptions in about 90 seconds

                • (18:17) - How Eyebot proved demand with a rough prototype and a “Free Vision Test” sign in a Boston mall

                • (29:01) - How clinical studies and iteration built the evidence retailers needed to trust the technology

                • (33:17) - What commercialization revealed about consumer behavior in eyewear retail

                • (37:07) - Matthias’s fundraising advice: run your raise over Zoom and don’t lead with your pitch deck

                • 51 min
                • How to Decide Where to Deploy Capital in Growth-Stage Medtech: Interview with CMR Surgical CEO Massimiliano (Max) Colella

                  In this episode, we sat down with Massimiliano (Max) Colella, CEO of CMR Surgical.

                  CMR Surgical is developing Versius, a surgical robot designed to make minimally invasive procedures more accessible across specialties.

                  Max brings more than three decades of healthcare leadership experience spanning medtech and hospital systems. He previously held leadership roles at Johnson & Johnson and Smith & Nephew across Europe, Asia Pacific, and the Middle East, and later served as CEO of Evercare Group, a TPG portfolio company.

                  In this interview, Max discusses how to prioritize capital allocation between platform development and product line expansion, when internal processes need restructuring, the importance of having the right culture, and why undertaking market research ahead of launching into a new market is crucial. He also shares his approach to hiring — and on maintaining clear board governance boundaries.

                  KEY MOMENTS FROM THE INTERVIEW

                  • (03:08) - An overview of Max's background and the journey that led him to CMR Surgical

                  • (06:53) - Why Max chose surgical robotics — and how Versius is designed to differentiate from existing systems

                  • (16:18) - How Max restructured internal processes at CMR to eliminate large-company bureaucracy

                  • (21:09) - How market research reshaped CMR’s U.S. strategy beyond ambulatory surgery centers

                  • (28:48) - Max’s capital allocation philosophy: prioritize system performance and stability before expanding capabilities

                  • (32:19) - Max's take on Techmed and the future of robotics

                  • (36:36) - Why clearly defined roles between board and management are critical for governance

                  • (41:10) - Max’s philosophy around hiring for mindset over skill

                  • 50 min
                  • Designing Consumer-Facing Medical Technology: Interview with Indomo CEO Rick Bente

                    In this episode, we sat down with Rick Bente, co-founder and CEO of Indomo.

                    Indomo’s flagship device, ClearPen, is an investigational at-home corticosteroid injection designed to treat inflammatory acne.

                    Rick has over 20 years of experience as an engineer and operator across medtech and pharma, with leadership roles at Medtronic, Insulet, and YourBio, focused on drug delivery and combination products. He is an inventor on more than 50 patents and has generated over $150 million in investments.

                    In this conversation, Rick discusses how Indomo translated an in-office dermatology procedure into at-home care, why usability had to be engineered rather than trained, how the company decided when to exit stealth mode, and how proof-based milestones shaped its fundraising.

                    KEY MOMENTS FROM THE INTERVIEW

                    • (03:39) - An overview of Rick’s background and the mission behind Indomo

                    • (08:24) - The core idea behind Indomo’s ClearPen — bringing dermatologist treatments into patients’ homes

                    • (13:32) - Why early-stage startups should fail fast on the hardest technical problems

                    • (16:41) - How to design medical devices that are easy to use and difficult to misuse

                    • (21:17) - How usability studies with patients and physicians shape better device design

                    • (23:59) - When should a startup stay in stealth — and when is it time to tell the story?

                    • (28:52) - Rick's fundraising playbook: mapping capital to milestones and real value creation

                    • (37:22) - Rick's hiring lesson: why curiosity matters more than pedigree when building an early-stage startup team

                    • 50 min
                    • Why Commercial Discipline Starts Long Before Launch: Interview with RenovoRx CEO Shaun Bagai

                      In this episode, we sat down with Shaun Bagai, CEO of RenovoRx. 

                      The company is developing targeted oncology therapies and is currently commercializing RenovoCath, which is focused on pancreatic cancer. 

                      Before joining RenovoRx in 2014, Shaun spent over a decade in the cardiovascular space, including leading global market development at HeartFlow and helping establish the European renal denervation market at Ardian, which Medtronic acquired for approximately $1 billion. He began his career in clinical research and device sales at TransVascular and Medtronic. 

                      In this interview, Shaun discusses how testing markets with minimal infrastructure reveals what leads to commercial success, why clinical trial enrollment benefits from sales discipline, and what founders should understand about going public when traditional capital isn't available.

                      57 min